Genzyme Corp. Receives European Approval for its Kidney Disease Drug Renvela (GENZ)

By Douglas A. McIntyre Updated Apr 27, 10:03PM EDT · Published Jun 13, 6:49AM EDT

Biotech Genzyme Corp. (Nasdaq: GENZ) reported on Friday that it has received European approval for Renvela, a newer version of its Renagel drug to help control phosphate levels in the blood of chronic kidney disease patients.

Genzyme ended trading on Friday down 0.59 (0.99%) with a closing trade price of 58.76.

The approval covers both tablet and powder formulations of the drug for kidney patients not yet on dialysis with high serum phosphorus lead that can lead to heart disease.

Both Renagel and Renvela treat hyperphosphatemia, the excess of phosphate in the blood, a risk factor for cardiovascular illnesses in patients with chronic kidney disease. Renvela can also control the buildup of serum phosphorus. High serum phosphorus levels can lead to calcification of tissues, where calcium buildup causes soft tissue to harden.

Genzyme is seeking more approvals for Renvela in the international market. The drug was launched in India this quarter for patients on dialysis and was approved in Brazil this week.

In the United States, the most important market, Renvela tablets were launched for patients on dialysis last March. The company expects FDA approval of the powder form of Renvela in the second half of this year.

However, Genzyme said Renvela’s approval in the broader pre-dialysis market would miss the company’s previously stated goal of mid-2009 U.S. approval. Despite the delay, Genzyme said its 2009 earnings forecast will not be affected.

Combined sales of Renvela and Renagel were $170.6 million in the first quarter. U.S. Renvela approval in pre-dialysis patients is expected to significantly boost sales.

“We continue to believe a label expansion is forthcoming, and perceive a sizable market opportunity in this indication once approved,” said Christopher Raymond, analyst for Robert W Baird.

Joshua Sherman

Follow 24/7 Wall St. on Google

About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.